- Stocks
- Healthcare
- OTC: ENZN

Price (delayed)

$0.339

Market cap

$25.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

-$23.03M

ENZN's revenue has surged by 66% since the previous quarter

The gross profit has soared by 66% from the previous quarter

The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter

The company's EPS fell by 33% YoY

What are the main financial stats of ENZN

Market
Valuations
Earnings

Shares outstanding

74.21M

Market cap

$25.16M

Enterprise value

-$23.03M

Price to earnings (P/E)

N/A

Price to book (P/B)

3.97

Price to sales (P/S)

35.24

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-32.26

Revenue

$714,000

EBIT

-$834,000

EBITDA

-$834,000

Free cash flow

-$794,000

Per share
Balance sheet
Liquidity

EPS

-$0.04

Free cash flow per share

-$0.01

Book value per share

$0.09

Revenue per share

$0.01

TBVPS

$0.65

Total assets

$48.25M

Total liabilities

$41.91M

Debt

$0

Equity

$6.34M

Working capital

$47.81M

Debt to equity

0

Current ratio

111.17

Quick ratio

111.04

Net debt/EBITDA

57.78

Margins
Efficiency
Dividend

EBITDA margin

-116.8%

Gross margin

100%

Net margin

-117.8%

Operating margin

-117.5%

Return on assets

-6.1%

Return on equity

-36%

Return on invested capital

N/A

Return on capital employed

-1.7%

Return on sales

-116.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Enzon Pharmaceuticals stock price performed over time

Intraday

-3.14%

1 week

-5.81%

1 month

-6.33%

1 year

111.88%

YTD

36.47%

QTD

-10.17%

How have Enzon Pharmaceuticals's revenue and profit performed over time

Revenue

$714,000

Gross profit

$714,000

Operating income

-$839,000

Net income

-$841,000

Gross margin

100%

Net margin

-117.8%

ENZN's net margin has surged by 93% year-on-year and by 52% since the previous quarter

ENZN's operating margin has soared by 93% YoY and by 52% from the previous quarter

ENZN's revenue has surged by 66% since the previous quarter

The gross profit has soared by 66% from the previous quarter

What is Enzon Pharmaceuticals's growth rate over time

What is Enzon Pharmaceuticals stock price valuation

P/E

N/A

P/B

3.97

P/S

35.24

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-32.26

The company's EPS fell by 33% YoY

The stock's price to book (P/B) is 99% more than its 5-year quarterly average of 2.0 but 19% less than its last 4 quarters average of 4.9

The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter

The P/S is 75% below the last 4 quarters average of 143.1 and 24% below the 5-year quarterly average of 46.3

ENZN's revenue has surged by 66% since the previous quarter

How efficient is Enzon Pharmaceuticals business performance

Enzon Pharmaceuticals's return on equity has shrunk by 101% YoY and by 11% QoQ

The company's return on sales has surged by 93% YoY and by 52% QoQ

ENZN's return on assets has surged by 56% year-on-year and by 19% since the previous quarter

What is ENZN's dividend history

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

Recent dividends

How did Enzon Pharmaceuticals financials performed over time

Enzon Pharmaceuticals's total assets is 15% more than its total liabilities

ENZN's quick ratio is up by 6% since the previous quarter

The current ratio has increased by 6% from the previous quarter

ENZN's debt is 100% smaller than its equity

The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.